[go: up one dir, main page]

MX2009002922A - Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico. - Google Patents

Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Info

Publication number
MX2009002922A
MX2009002922A MX2009002922A MX2009002922A MX2009002922A MX 2009002922 A MX2009002922 A MX 2009002922A MX 2009002922 A MX2009002922 A MX 2009002922A MX 2009002922 A MX2009002922 A MX 2009002922A MX 2009002922 A MX2009002922 A MX 2009002922A
Authority
MX
Mexico
Prior art keywords
azetidone
azetidine
disorders
treating pain
lipid metabolism
Prior art date
Application number
MX2009002922A
Other languages
English (en)
Inventor
Brian Mckittrick
Duane A Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009002922A publication Critical patent/MX2009002922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se descrien compuestos de la fórmula (I) (ver fórmula (I)) en donde Z1 es -CH2- o -C(O)-, R4 y R5 son cadenas de carbono (y opcionalmente, conjuntamente pueden formar un puente C2), u y v son independientemente un entero de 0-3 tal que la suma sea de 3 a 5 y R2 es heteroarilo, y R1 y R3 son según se definen en la presente; también se describen métodos de tratamiento del dolor, y métodos de inhibición de la absorción del colesterol que utilizan un compuesto de la fórmula I.
MX2009002922A 2006-09-15 2007-09-13 Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico. MX2009002922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84507606P 2006-09-15 2006-09-15
PCT/US2007/019934 WO2008033468A2 (en) 2006-09-15 2007-09-13 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism

Publications (1)

Publication Number Publication Date
MX2009002922A true MX2009002922A (es) 2009-04-01

Family

ID=39048975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002922A MX2009002922A (es) 2006-09-15 2007-09-13 Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Country Status (12)

Country Link
US (1) US7902157B2 (es)
EP (1) EP2061796A2 (es)
JP (1) JP2010503679A (es)
KR (1) KR20090071589A (es)
CN (1) CN101541805A (es)
AR (1) AR062791A1 (es)
AU (1) AU2007294771A1 (es)
CA (1) CA2663504A1 (es)
IL (1) IL197567A0 (es)
MX (1) MX2009002922A (es)
TW (1) TW200819453A (es)
WO (1) WO2008033468A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061791A1 (en) * 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
US20080076750A1 (en) * 2006-09-15 2008-03-27 Aslanian Robert G Azetidinone Derivatives and Methods of Use Thereof
US7884080B2 (en) * 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP2905276A4 (en) * 2012-09-05 2016-03-09 Zhejiang Hisun Pharm Co Ltd CRYSTALLINE FORMS OF AZETIDINONE COMPOUNDS AND METHODS FOR PREPARING THE SAME
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
KR102364840B1 (ko) * 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
WO2020113077A1 (en) 2018-11-29 2020-06-04 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6075457A (ja) 1983-06-11 1985-04-27 Osaka Soda Co Ltd ３，４−ジフェニル−１−ベンジルアゼチジン−２−オンの製法
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1999000393A1 (en) 1997-06-26 1999-01-07 Dong Wha Pharmaceutical Industrial Co., Ltd. Quinolone carboxylic acid derivatives
US6316638B1 (en) 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EP1519939B9 (en) 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
WO2005046797A2 (en) 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1598336A1 (en) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams
US7291728B2 (en) * 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
WO2005116009A1 (en) 2004-05-18 2005-12-08 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
CN101534822A (zh) * 2006-09-15 2009-09-16 先灵公司 治疗疼痛、糖尿病和脂质代谢紊乱
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
US20080070888A1 (en) * 2006-09-15 2008-03-20 Mckittrick Brian A Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
US7884080B2 (en) * 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
EP2061791A1 (en) * 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
US20080076750A1 (en) * 2006-09-15 2008-03-27 Aslanian Robert G Azetidinone Derivatives and Methods of Use Thereof

Also Published As

Publication number Publication date
EP2061796A2 (en) 2009-05-27
CN101541805A (zh) 2009-09-23
WO2008033468A2 (en) 2008-03-20
AU2007294771A1 (en) 2008-03-20
IL197567A0 (en) 2009-12-24
US7902157B2 (en) 2011-03-08
CA2663504A1 (en) 2008-03-20
KR20090071589A (ko) 2009-07-01
TW200819453A (en) 2008-05-01
JP2010503679A (ja) 2010-02-04
US20080070889A1 (en) 2008-03-20
WO2008033468A3 (en) 2008-08-14
AR062791A1 (es) 2008-12-03

Similar Documents

Publication Publication Date Title
MX2009002922A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
MX2009002919A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
WO2009049180A3 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
TNSN06005A1 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
PL377847A1 (pl) 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
TW200505919A (en) DPP-IV inhibitors
NZ606263A (en) Sliding panel suspension system
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
IL189156A (en) A bite-containing (theo-hydrazide-rich) preparation, a flake cation and a thickening additive, a method for making this lipophilate and the leophilizate
SG170739A1 (en) Iap bir domain binding compounds
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
NO20054476D0 (no) Forbindelser for behandling av smerte
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
SE0401969D0 (sv) Piperidine derivatives